2011
DOI: 10.1182/blood-2010-05-284711
|View full text |Cite
|
Sign up to set email alerts
|

Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection

Abstract: Regulated by histone acetyltransferases and deacetylases (HDACs), histone acetylation is a key epigenetic mechanism controlling chromatin structure, DNA accessibility, and gene expression.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

35
287
0
4

Year Published

2012
2012
2019
2019

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 300 publications
(331 citation statements)
references
References 50 publications
35
287
0
4
Order By: Relevance
“…Bacteria were grown to log phase in brain-heart infusion medium, washed, and resuspended in PBS at an OD 620 of 1.0. Whole blood from five healthy Caucasian subjects was drawn into S-monovette-tubes (Sarstedt) containing 16 U of heparin per mL, diluted fivefold in phenol red-free RPMI medium 1640 containing 2 mM L-glutamine (Life Technologies) (52). Blood was incubated at 37°C with S. pneumoniae (53).…”
Section: Methodsmentioning
confidence: 99%
“…Bacteria were grown to log phase in brain-heart infusion medium, washed, and resuspended in PBS at an OD 620 of 1.0. Whole blood from five healthy Caucasian subjects was drawn into S-monovette-tubes (Sarstedt) containing 16 U of heparin per mL, diluted fivefold in phenol red-free RPMI medium 1640 containing 2 mM L-glutamine (Life Technologies) (52). Blood was incubated at 37°C with S. pneumoniae (53).…”
Section: Methodsmentioning
confidence: 99%
“…17,18 Other than chromatin proteins, transcription factors and cell-signaling regulatory proteins could also be the substrates for HDACs. 19 Particularly, HDAC superfamily has been receiving increasing attention for its role in modulating both innate and adaptive immune responses 20,21 implicatd in allograft survival and transplantation outcome. 22 As such, HDAC inhibitors (HDACis) are now under intensive study for their feasibility as potential anti-rejection agents.…”
Section: Introductionmentioning
confidence: 99%
“…Small-molecule inhibitors of HDACs that have been developed as antican-cer agents (13) also reportedly have therapeutic effects in a range of inflammatory disease models (14). These anti-inflammatory effects likely result from the regulation of multiple immune cell types, including T regulatory cells (15), Th17 cells, (16), macrophages (17)(18)(19)(20), and dendritic cells (21). In macrophages, HDAC inhibitors reduce TLR-inducible production of a subset of proinflammatory cytokines, including TNF␣, IL-12, IL-6, chemokines such as monocyte chemoattractant proteins 1 and 3, and other inflammatory mediators, including endothelin 1 (ET-1) (17,18,20,22,23).…”
mentioning
confidence: 99%
“…These anti-inflammatory effects likely result from the regulation of multiple immune cell types, including T regulatory cells (15), Th17 cells, (16), macrophages (17)(18)(19)(20), and dendritic cells (21). In macrophages, HDAC inhibitors reduce TLR-inducible production of a subset of proinflammatory cytokines, including TNF␣, IL-12, IL-6, chemokines such as monocyte chemoattractant proteins 1 and 3, and other inflammatory mediators, including endothelin 1 (ET-1) (17,18,20,22,23). The mechanisms by which they do so remain poorly understood but may involve the impairment of transcription factor recruitment to target promoters (22) and inhibition of mitogen-activated protein kinase p38 signaling (10).…”
mentioning
confidence: 99%